Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

J&J Inks $14.6 Billion Intra-Cellular Therapies Deal

The deal is expected to be finalized by the first half of this year. 

Merck Purchases WuXi Vaccine Plant in Ireland for $520 Million

Videos

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the difference between return on invested capital in pharma compared to other organizations. 

Trade & Channel Strategies 2024: The Significance of Return on Invested Capital for Pharma Companies

Podcasts

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report. 

The Path Forward for Infused Biosimilars in the US

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia. 

Novo Nordisk Financially Commits $1.2 Billion Toward New Danish Production Plant

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

Trade & Channel Strategies 2024: Navigating Pharma and Its Distribution Models

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year. 

Trade & Channel Strategies 2024: Access and Channel 2024 Year-in-Review and Preview of 2025

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

Examining Launch, Post-Launch Price Developments in the United States and Europe

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities. 

Business and Finance